Health · Medical Research · 5 hrs ago
Study links rare gut complication after CAR T therapy to persistent cells
Researchers studied a rare gut complication after CAR T treatment in people with multiple myeloma, a blood cancer.
The condition, called IEC-EC, can cause lasting diarrhea and inflammation, and may lead to long hospital stays, intensive nutritional support and increased risk of death.
Among 158 patients given the CAR T treatment cilta-cel, nine developed IEC-EC, or about 5%.
Those patients had about 100 times more CAR T cells persisting in their blood than patients who did not develop the condition.
Tests of tissue samples found CAR T cells in the digestive tract, where they appeared to drive ongoing inflammation and damage.
The findings suggest that monitoring CAR T cells may help flag risk earlier, while examining the upper small intestine and testing tissue for CAR T cells could help diagnose the condition.
More studies are needed to identify who is most at risk and how to prevent the complication.
A study found that patients with multiple myeloma who developed a rare gut complication after CAR T therapy had far more CAR T cells persisting in their blood.
The condition, called immune effector cell-associated enterocolitis (IEC-EC), occurred in about 5% of patients treated with cilta-cel in the study.
Researchers analyzed nine cases among 158 patients and found roughly 100-fold higher long-term CAR T cell levels in affected patients.
Tissue samples showed CAR T cells accumulating in the digestive tract, where they appeared to drive ongoing inflammation and damage.
The findings, published in Nature Medicine, may help clinicians identify and treat the complication earlier.
- Who
- Researchers at The University of Texas MD Anderson Cancer Center studied patients with multiple myeloma treated with cilta-cel.
- What
- The study linked IEC-EC, a serious gastrointestinal complication, to higher persistent CAR T cell levels.
- When
- Published on November 19, 2026.
- Where
- The study analyzed patients treated with cilta-cel; the study was published in Nature Medicine.
- Why
- Researchers investigated the cause of IEC-EC to improve recognition, monitoring and treatment.
This story does not have two clearly opposing sides.
Some patients developed IEC-EC, with persistent diarrhea and inflammation.
Researchers analyzed nine cases among 158 patients and found higher CAR T cell persistence in affected patients.
The study was reported as published in Nature Medicine.
- Study treatment
- Ciltacabtagene autoleucel (cilta-cel)
- Study cases
- 9 cases of IEC-EC among 158 patients
- Incidence
- Approximately 5% of patients treated with cilta-cel
- CAR T cell levels
- Roughly 100-fold higher in affected patients
- Journal
- Nature Medicine
1 source
What people are saying
Our study found that IEC-EC is not just inflammation of the gastrointestinal tract, but it is a distinct CAR T cell therapy-driven immune cell disorder.